| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d4ad61d0af1fd483d31d1c5df9b9b76 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2250-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-324 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 |
| filingDate |
2022-04-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a92d927369598b55e88aefbfffeb3f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed3445d0c62bccb051a53ad08a38156a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79857280b5873125d336e6d127594b1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4371e1f548a2e3e0a63a692a3eb78163
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3495b94fa866dcc97e2dc72255b27e74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9705ffb18124fcd3ef816b91dc88fe02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ecce7fb349383152bcb8e56f4281d02d |
| publicationDate |
2022-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022220478-A1 |
| titleOfInvention |
Pharmaceutical composition comprising novel sd911 compound as active ingredient for prevention or treatment of transplant rejection |
| abstract |
The present invention relates to a pharmaceutical composition comprising a novel compound as an active ingredient for prevention or treatment of transplant rejection. The novel compound SD911 of the present invention was identified to repress the migration of immune cells, increase the engraftment and viability of a grafted tissue, and regulate immune cells. In addition, it was found in a kidney transplantation model that the compound restrained human PBMC from suppressing the engraftment and damaging renal tissues and downregulated the expression of the inflammatory cytokine IL-17, with the consequent effective prevention and treatment of transplant rejection. |
| priorityDate |
2021-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |